Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > 12/13 Goblet PC patients had Stage IV metastatic (M1) cancer

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Dec 06, 2022 3:42pm

108 Views

Post# 35154317

RE:RE:RE:RE:RE:RE:RE:12/13 Goblet PC patients had Stage IV metastatic (M1) cancer

GOBLET There appears to have been one patient that was not Stage IV. That is to say I think ,that one patient was not metastatic. Said patient did not have a spread to another organ.

So we have 12 patients that were metastatic, many but not all to the liver.

The question remains; can we ascertain if the complete response was in the one non Stage IV, or in the STAGE IV group. From my lay perspective one would think the CR was in the non-metastatic patient. Anyone. TIA

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta